Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeyondSpring Inc.    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
14.65(c) 15.07(c) 14.59(c) 14.54(c) 14.74(c) Last
78 845 48 666 91 153 66 265 88 397 Volume
-1.21% +2.87% -3.19% -0.34% +1.38% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -60,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,99x
Yield 2020 -
Sales 2021 14,4 M - -
Net income 2021 -102 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,29x
Yield 2021 -
Capitalization 438 M 438 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 30,3x
Nbr of Employees 61
Free-Float 12,0%
More Financials
Company
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived... 
More about the company
Notations Surperformance© of BeyondSpring Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about BEYONDSPRING INC.
10/14Seed Therapeutics Launches Protein Degradation Research Platform and Appoints..
GL
10/12BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veter..
GL
09/29JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Ind..
GL
09/24New Data Highlights BeyondSpring's Plinabulin as a Highly Effective Agent for..
GL
09/22BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
GL
09/17BEYONDSPRING : Corporate Presentation
PU
09/11BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment ..
GL
09/08BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA an..
GL
09/03BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Upda..
GL
08/27BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Up..
GL
08/18BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology V..
GL
08/11BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients S..
GL
06/30New Stem Cell-Based Application for BeyondSpring's Plinabulin Presented at IS..
GL
06/25BEYONDSPRING : 2020 First Quarter Financial Report
PU
06/23New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Comb..
GL
More news
News in other languages on BEYONDSPRING INC.
05/20BEYONDSPRING INC. : Veröffentlichung des Quartalsergebnisses
05/20BEYONDSPRING INC. : publication des résultats trimestriels
More news
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 41,50 $
Last Close Price 14,54 $
Spread / Highest target 216%
Spread / Average Target 185%
Spread / Lowest Target 154%
EPS Revisions
Managers
NameTitle
Lan Huang Chairman & Chief Executive Officer
Richard J. Daly Chief Operating Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director & Chief Medical Officer
James Tonra Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BEYONDSPRING INC.-6.19%438
GILEAD SCIENCES, INC.-9.93%73 380
REGENERON PHARMACEUTICALS48.02%58 486
VERTEX PHARMACEUTICALS-5.45%53 919
WUXI APPTEC CO., LTD.71.35%40 739
BEIGENE, LTD.80.68%27 143